RAND Corporation, Arlington, VA, United States of America.
RAND Corporation, Arlington, VA, United States of America.
J Affect Disord. 2022 Dec 15;319:507-510. doi: 10.1016/j.jad.2022.08.119. Epub 2022 Aug 31.
This study examined whether the COVID-19 pandemic was associated with changes in new selective serotonin reuptake inhibitor (SSRI) prescription fills.
Using IQVIA Xponent data on new SSRI fills in Los Angeles (L.A.) County from March 2019 to June 2021, the authors implemented an interrupted time series analysis comparing the monthly volume and trend of overall fills and fills by age and gender from before to after the pandemic declaration.
The rate of new SSRI prescription fills briefly decreased after the pandemic declaration but then consistently increased through the rest of the study period. These increases were primarily driven by women, young adults (i.e., 18-39 year-olds), and those under 18 years old.
Sample is limited to one county and may not be generalizable to other municipalities.
The COVID-19 pandemic was associated with significant increases in new SSRI fills among women, young adults, and those under 18. These increases were relatively small compared to increases in depressive symptoms during the same time period.
本研究旨在探讨 COVID-19 大流行是否与新型选择性 5-羟色胺再摄取抑制剂（SSRI）处方量的变化有关。
本研究使用 IQVIA Xponent 数据，对 2019 年 3 月至 2021 年 6 月期间洛杉矶县（L.A.）的新型 SSRI 处方用量进行了分析，采用中断时间序列分析，比较了大流行宣布前后整体处方量以及按年龄和性别划分的处方量的月度变化和趋势。
大流行宣布后，新型 SSRI 处方量的比率短暂下降，但随后在研究期间持续增加。这些增长主要由女性、年轻成年人（即 18-39 岁）和 18 岁以下人群推动。
样本仅限于一个县，可能无法推广到其他城市。
COVID-19 大流行与女性、年轻成年人和 18 岁以下人群新型 SSRI 处方量的显著增加有关。与同期抑郁症状的增加相比，这些增长相对较小。
